These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 17082691)

  • 21. [Combined use of PSA density and free to total PSA ratio for cancer detection from patients with PSA elevations].
    Kawai M; Okajima K; Kobayashi K; Moriyama M
    Hinyokika Kiyo; 2006 Feb; 52(2):113-7. PubMed ID: 16541764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA.
    Padhani AR; Gapinski CJ; Macvicar DA; Parker GJ; Suckling J; Revell PB; Leach MO; Dearnaley DP; Husband JE
    Clin Radiol; 2000 Feb; 55(2):99-109. PubMed ID: 10657154
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [PSA and PSAD study in patients with renal dysfunction].
    Sánchez de la Muela P; González Parra E; Blasco R; Vallejo J; Fanlo B; Melgarejo M; Martín-Laborda F; Ortíz A; Labanda P
    Actas Urol Esp; 1996 Mar; 20(3):255-60. PubMed ID: 8712042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is there a role for serum human tissue kallikrein in detection of prostate cancer?
    Ochiai A; Shukla A; Davis JW; Fritsche HA; Bhadkamkar V; Babaian RJ
    Urology; 2007 Sep; 70(3):519-22. PubMed ID: 17905108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of prostate-specific antigen level at diagnosis on the relative survival of 28,531 men with localized carcinoma of the prostate.
    Sandblom G; Ladjevardi S; Garmo H; Varenhorst E
    Cancer; 2008 Feb; 112(4):813-9. PubMed ID: 18098207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound.
    Cirillo S; Petracchini M; D'Urso L; Dellamonica P; Illing R; Regge D; Muto G
    BJU Int; 2008 Aug; 102(4):452-8. PubMed ID: 18476973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Validity of PSA density of the transition zone in the diagnosis of prostate cancer].
    Anastasi G; Magno C; Carmignani A; Inferrera A; Petrelli A; Broccio G
    Arch Ital Urol Androl; 2000 Dec; 72(4):190-3. PubMed ID: 11221034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and clinical significance of prostate cancer among 12,682 men with normal digital rectal examination, low PSA levels (< or =4 ng/ml) and percent free PSA cutoff values of 15 and 20%.
    Pepe P; Panella P; Savoca F; Cacciola A; D'Arrigo L; Dibenedetto G; Pennisi M; Aragona F
    Urol Int; 2007; 78(4):308-12. PubMed ID: 17495487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Value of prostate specific antigen in early diagnosis of prostatic cancer].
    Xiao LP; Bi XJ; Li YN; Chen XQ; Zhang XF; Yu XP; Liu G; Yang MC; Song Z
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jan; 27(1):107-8, 112. PubMed ID: 17259162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for prostate cancer patients with intermediate PSA levels.
    Tanaka N; Fujimoto K; Chihara Y; Torimoto M; Hirao Y; Konishi N; Saito I
    Prostate Cancer Prostatic Dis; 2007; 10(3):274-8. PubMed ID: 17339878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant radiotherapy in prostate cancer: predictors of prostate-specific antigen recurrence from the CaPSURE database.
    Macdonald OK; D'Amico AV; Sadetsky N; Shrieve DC; Carroll PR
    Urology; 2007 Jul; 70(1):106-10. PubMed ID: 17656218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of magnetic resonance imaging-based prostate-specific antigen density of the prostate in the diagnosis of prostate cancer.
    Hoshii T; Nishiyama T; Toyabe S; Akazawa K; Komatsu S; Kaneko M; Hara N; Takahashi K
    Int J Urol; 2007 Apr; 14(4):305-10. PubMed ID: 17470159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
    Leibovici D; Spiess PE; Agarwal PK; Tu SM; Pettaway CA; Hitzhusen K; Millikan RE; Pisters LL
    Cancer; 2007 Jan; 109(2):198-204. PubMed ID: 17171704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Differentiation of prostate cancer from benign prostatic disease by total prostate specific antigen dynamic profiles after transrectal prostate biopsy].
    Shao Q; Song J; Zhou ZJ; Du LD
    Zhonghua Nan Ke Xue; 2008 Jul; 14(7):597-601. PubMed ID: 18686378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.
    Walz J; Haese A; Scattoni V; Steuber T; Chun FK; Briganti A; Montorsi F; Graefen M; Huland H; Karakiewicz PI
    Cancer; 2008 Nov; 113(10):2695-703. PubMed ID: 18853417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials.
    Nanda A; Chen MH; Renshaw AA; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1419-23. PubMed ID: 19131185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter.
    Ahyai SA; Graefen M; Steuber T; Haese A; Schlomm T; Walz J; Köllermann J; Briganti A; Zacharias M; Friedrich MG; Karakiewicz PI; Montorsi F; Huland H; Chun FK
    Eur Urol; 2008 Apr; 53(4):750-7. PubMed ID: 17964070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does prostate biopsy Gleason score accurately express the biologic features of prostate cancer?
    Stav K; Judith S; Merald H; Leibovici D; Lindner A; Zisman A
    Urol Oncol; 2007; 25(5):383-6. PubMed ID: 17826654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prebiopsy PSA velocity not reliable predictor of prostate cancer diagnosis, Gleason score, tumor location, or cancer volume after TTMB.
    Bittner N; Merrick GS; Andreini H; Taubenslag W; Allen ZA; Butler WM; Anderson RL; Adamovich E; Wallner KE
    Urology; 2009 Jul; 74(1):171-6. PubMed ID: 19232691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.